These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 9551749)
1. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Wencker M; Banik N; Buhl R; Seidel R; Konietzko N Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749 [TBL] [Abstract][Full Text] [Related]
2. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Seersholm N; Wencker M; Banik N; Viskum K; Dirksen A; Kok-Jensen A; Konietzko N Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950 [TBL] [Abstract][Full Text] [Related]
3. [Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin]. Wencker M; Banik N; Buhl R; Seidel R; Konietzko N Pneumologie; 1998 Oct; 52(10):545-52. PubMed ID: 9847632 [TBL] [Abstract][Full Text] [Related]
4. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Chapman KR; Burdon JG; Piitulainen E; Sandhaus RA; Seersholm N; Stocks JM; Stoel BC; Huang L; Yao Z; Edelman JM; McElvaney NG; Lancet; 2015 Jul; 386(9991):360-8. PubMed ID: 26026936 [TBL] [Abstract][Full Text] [Related]
5. α1-Proteinase inhibitor (human) in the treatment of hereditary emphysema secondary to α1-antitrypsin deficiency: number and costs of years of life gained. Sclar DA; Evans MA; Robison LM; Skaer TL Clin Drug Investig; 2012 May; 32(5):353-60. PubMed ID: 22480280 [TBL] [Abstract][Full Text] [Related]
6. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency. Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of augmentation therapy for emphysema associated with α1-antitrypsin deficiency: enough is enough. Balbi B; Ferrarotti I; Miravitlles M Eur Respir J; 2016 Jan; 47(1):35-8. PubMed ID: 26721962 [No Abstract] [Full Text] [Related]
12. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med; 1998 Jul; 158(1):49-59. PubMed ID: 9655706 [TBL] [Abstract][Full Text] [Related]
14. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Wencker M; Fuhrmann B; Banik N; Konietzko N; Chest; 2001 Mar; 119(3):737-44. PubMed ID: 11243951 [TBL] [Abstract][Full Text] [Related]
15. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314 [TBL] [Abstract][Full Text] [Related]
16. Safety of biweekly α Greulich T; Chlumsky J; Wencker M; Vit O; Fries M; Chung T; Shebl A; Vogelmeier C; Chapman KR; McElvaney NG; Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30237305 [TBL] [Abstract][Full Text] [Related]
17. Lung disease due to alpha 1-antitrypsin deficiency. Wiedemann HP; Stoller JK Curr Opin Pulm Med; 1996 Mar; 2(2):155-60. PubMed ID: 9363132 [TBL] [Abstract][Full Text] [Related]
18. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Kueppers F Curr Med Res Opin; 2011 Mar; 27(3):579-88. PubMed ID: 21226542 [TBL] [Abstract][Full Text] [Related]